Study the potential of 1,5-anhydroglucitol index in evaluating short-term blood glucose fluctuations and its relationship with risk factors in type 2 diabetes patients
Main Article Content
Abstract
To determine the concentration of 1,5-Anhydroglucitol (1,5-AG) in patients with type 2 diabetes and analyze the correlation between the 1,5-AG index and other biomarkers such as HbA1c, fructosamine, plasma glucose. Evaluate the influence of individual risk factors such as smoking, and alcohol consumption on correlations. A case-control study conducted on 50 patients with T2D and 50 healthy controls at Da Nang Hospital. The average concentration of 1,5-AG in the case group was 10.91 ± 6.53 µg/mL, the control group’s 26.83 ± 9.98 µg/mL, p < 0.001. In T2D patients, there was an inverse correlation between 1,5-AG levels and HbA1c, fasting blood glucose, and fructosamine (r = -0.59; r = -0.43; r = -0.48; p < 0.001). Factors like smoking history, and alcohol addiction significantly increased the correlation between 1,5-AG and these parameters. Changes in 1,5-AG levels are significant for evaluating short-term blood glucose fluctuations in T2D patients.
Article Details
Keywords
1,5-Anhydroglucitol, type 2 diabetes, risk factors
References
2. Lâm Vĩnh Niên, Nguyễn Quỳnh Mai Nguyệt. Đánh giá sự thay đổi theo thời gian và vai trò của 1,5-Anhydroglucitol trong kiểm soát đường huyết. Tạp chí Y học Việt Nam. 2022; 515(1): 40-45.
3. Phạm Thị Thu Trang, Đỗ Ngọc Hải, Đào Văn Tùng, và cs. Nghiên cứu vai trò xét nghiệm Glycomark (1,5 AG) trong theo dõi điều trị bệnh nhân đái tháo đường type 2. Tạp chí Y học Việt Nam. 2022; 515: 327-334.
4. Trần Thành Vinh, Lâm Vĩnh Niên, Dương Hà Khánh Linh. Khảo sát nồng độ 1,5-Anhydroglucitol trong máu bệnh nhân đái tháo đường type 2 tại Bệnh viện Chợ Rẫy. Tạp chí Y học Việt Nam. 2022; 517(1): 174-178.
5. McGill JB, Cole TG, Nowatzke W, et al. Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia. Diabetes Care. 2004-08-01 2004; 27(8): 1859-1865. doi:10.2337/diacare.27.8.1859.
6. Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. The Lancet. 06/1996 1996; 347(9014): 1514-1518. doi:10.1016/S0140-6736(96)90672-8.
7. Kwon PS, Rheem I. The Assessment of Blood Glucose Distribution according to the Fasting State and Glycemic Control Indicators for Diabetes Screening. The Korean Journal of Clinical Laboratory Science. 2016-12-31 2016; 48(4): 312-320. doi:10.15324/kjcls.2016.48.4.312.
8. Dandona P. Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. Diabetes Technol Ther. Sep 2017; 19(9): 498-506. doi:10.1089/dia.2016.0372.
9. Association AD. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2019-01 2020; 42(Suppl 1): S13-S28. doi:10.2337/dc19-S002.
10. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. Nov 1 2022; 43(41): 4229-4361. doi:10.1093/eurheartj/ehac244.
11. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. Jun 1993; 88(6): 791-804. doi:10.1111/j.1360-0443.1993.tb02093.x.
12. Dungan KM. 1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions. Expert Review of Molecular Diagnostics. 01/2008 2008; 8(1): 9-19. doi:10.1586/14737159.8.1.9.